Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol preferring rats chronically treated with lamotrigine. 2015

Jadwiga Zalewska-Kaszubska, and Bartosz Bajer, and Dorota Gorska, and Dariusz Andrzejczak, and Wanda Dyr, and Przemysław Bieńkowski
Department of Pharmacodynamics, Medical University of Lodz, Muszynskiego 1, PL 90-151 Lodz, Poland. Electronic address: jadwiga.zalewska-kaszubska@umed.lodz.pl.

Several recent studies have indicated that lamotrigine, similarly to other antiepileptic drugs, may be useful in the therapy of alcohol dependence. The rationale for using lamotrigine in the treatment of alcohol addiction is based on its multiple mechanisms of action which include inhibition of voltage-sensitive sodium channels, modulation voltage-gated calcium currents and transient potassium outward current. However, the known mechanism of lamotrigine does not fully explain its efficacy in alcohol addiction therapy. For this reason we have decided to examine the effect of lamotrigine on the opioid system. Our previous studies showed that topiramate and levetiracetam (antiepileptic drugs) as well as the most effective drugs in alcohol addiction therapy i.e. naltrexone and acamprosate, when given repeatedly, all increased plasma beta endorphin (an endogenous opioid peptide) level, despite operating through different pharmacological mechanisms. It is known that low beta-endorphin level is often associated with alcohol addiction and also that alcohol consumption elevates the level of this peptide. This study aims to assess the effect of repeated treatment with lamotrigine on voluntary alcohol intake and beta-endorphin plasma level in alcohol preferring rats (Warsaw high preferring (WHP) rats). We observed a decrease in alcohol consumption in rats treated with lamotrigine. However we didn't observe significant changes in beta-endorphin level during withdrawal of alcohol, which may indicate that the drug does not affect the opioid system. We suppose that lamotrigine may be useful in alcohol dependence therapy and presents a potential area for further study.

UI MeSH Term Description Entries
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004326 Drinking The consumption of liquids. Water Consumption,Water Intake,Drinkings
D005260 Female Females
D000077213 Lamotrigine A phenyltriazine compound, sodium and calcium channel blocker that is used for the treatment of SEIZURES and BIPOLAR DISORDER. 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine,3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine,BW-430C,Crisomet,Labileno,Lamictal,Lamiktal,BW 430C,BW430C
D000428 Alcohol Drinking Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking. Alcohol Consumption,Alcohol Intake,Drinking, Alcohol,Alcohol Drinking Habits,Alcohol Drinking Habit,Alcohol Intakes,Consumption, Alcohol,Drinking Habit, Alcohol,Habit, Alcohol Drinking,Habits, Alcohol Drinking,Intake, Alcohol
D000431 Ethanol A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in ALCOHOLIC BEVERAGES. Alcohol, Ethyl,Absolute Alcohol,Grain Alcohol,Alcohol, Absolute,Alcohol, Grain,Ethyl Alcohol
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Jadwiga Zalewska-Kaszubska, and Bartosz Bajer, and Dorota Gorska, and Dariusz Andrzejczak, and Wanda Dyr, and Przemysław Bieńkowski
March 2008, Physiology & behavior,
Jadwiga Zalewska-Kaszubska, and Bartosz Bajer, and Dorota Gorska, and Dariusz Andrzejczak, and Wanda Dyr, and Przemysław Bieńkowski
September 2006, Pharmacology, biochemistry, and behavior,
Jadwiga Zalewska-Kaszubska, and Bartosz Bajer, and Dorota Gorska, and Dariusz Andrzejczak, and Wanda Dyr, and Przemysław Bieńkowski
October 2009, Alcoholism, clinical and experimental research,
Jadwiga Zalewska-Kaszubska, and Bartosz Bajer, and Dorota Gorska, and Dariusz Andrzejczak, and Wanda Dyr, and Przemysław Bieńkowski
September 1993, Pharmacology & toxicology,
Jadwiga Zalewska-Kaszubska, and Bartosz Bajer, and Dorota Gorska, and Dariusz Andrzejczak, and Wanda Dyr, and Przemysław Bieńkowski
February 2008, Neuroscience letters,
Jadwiga Zalewska-Kaszubska, and Bartosz Bajer, and Dorota Gorska, and Dariusz Andrzejczak, and Wanda Dyr, and Przemysław Bieńkowski
September 1995, Pharmacology, biochemistry, and behavior,
Jadwiga Zalewska-Kaszubska, and Bartosz Bajer, and Dorota Gorska, and Dariusz Andrzejczak, and Wanda Dyr, and Przemysław Bieńkowski
October 2005, European journal of pharmacology,
Jadwiga Zalewska-Kaszubska, and Bartosz Bajer, and Dorota Gorska, and Dariusz Andrzejczak, and Wanda Dyr, and Przemysław Bieńkowski
January 2011, Alcohol and alcoholism (Oxford, Oxfordshire),
Jadwiga Zalewska-Kaszubska, and Bartosz Bajer, and Dorota Gorska, and Dariusz Andrzejczak, and Wanda Dyr, and Przemysław Bieńkowski
January 1990, Progress in neuro-psychopharmacology & biological psychiatry,
Jadwiga Zalewska-Kaszubska, and Bartosz Bajer, and Dorota Gorska, and Dariusz Andrzejczak, and Wanda Dyr, and Przemysław Bieńkowski
January 2015, PloS one,
Copied contents to your clipboard!